Clinical Trial Search

Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants

Primary: Treatment Target: Change in Parental Empowerment Scale — 4.93; 0.61 score on a scale (change score) — p=.092

Primary: Change in Number of Hospital Transfers Pre/Post Intervention — 0.97; 0.65; NA hospital transfers per 1000 person days

Primary: Facilitators and Barriers to Implementing Decision Aids, Provider Notifications, and Personal Risk Calculation Using an Electronic Health Record (EHR) to Promote…

Primary: Average Daily Hours of Hearing Aid Use — 7.37; 7.20 Daily hours — p=0.92

Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells

Primary: Double Blind (DB) Period: Mean Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -2.8…

Primary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 35023; 25987 Extended-Spectrum Days-of-Therapy

Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants

Primary: Weight Change — -5.5; -4.1; -5.3; -5.1 kg

Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants

Primary: Change in SARS-CoV-2 Testing Rate (Practices) — 0.9928; 1 proportion of patients (ranging 0-1)

Primary: Study Device Sensitivity — 88.9 percent of ground truth positive cases

Primary: Opioid Tapering Rate, Category 1 — 0.0193; 0.0359; 0.0268; 0.0192 proportion

Primary: Complete Remission Rate — 31; 42 Participants